TRAW
Traws Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$13.20M
P/E Ratio
1.58
EPS
$0.82
Beta
1.62
52W High
$3.27
52W Low
$0.97
50-Day MA
$1.66
200-Day MA
$1.88
Dividend Yield
—
Profit Margin
328.70%
Forward P/E
—
PEG Ratio
—
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
Fundamentals
| Revenue (TTM) | $2.79M |
| Gross Profit (TTM) | $2.79M |
| EBITDA | $-17.81M |
| Operating Margin | -641.00% |
| Return on Equity | -1060.00% |
| Return on Assets | -62.80% |
| Revenue/Share (TTM) | $0.34 |
| Book Value | $0.64 |
| Price-to-Book | 2.16 |
| Price-to-Sales (TTM) | 4.73 |
| EV/Revenue | 3.345 |
| EV/EBITDA | 0.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $10.16M |
| Float | $5.96M |
| % Insiders | 15.60% |
| % Institutions | 33.66% |
Historical Volatility
HV 10-Day
106.01%
HV 20-Day
128.88%
HV 30-Day
116.96%
HV 60-Day
114.74%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($5.50 target)
2
BuyData last updated: 4/30/2026